M&A - Orgenesis Inc.
Form Type: 8-K
Filing Date: 2025-03-06
Corporate Action: Acquisition
Type: New
Accession Number: 000149315225009380
Filing Summary: On February 28, 2025, Orgenesis Inc. entered into an Asset Purchase Agreement with Neurocords, LLC for the acquisition of specific intellectual property assets and development products related to advanced regenerative medicine therapies targeting spinal cord injuries. As part of the agreement, the Company will issue 1,200,000 shares of common stock, free of trading restrictions after a six-month period. The agreement also includes mutual releases against future claims and the termination of prior licensing agreements. The acquisition was completed on March 3, 2025, following the provisions outlined in the purchase agreement, which includes customary representations, warranties, and covenants.
Document Link: View Document
Additional details:
Item Name: asset_purchase_agreement_date
Item Value: 2025-02-28
Item Name: acquired_assets_description
Item Value: intellectual property assets and all development product, deliverables and data related to advanced regenerative medicine therapies for spinal cord injuries
Item Name: shares_issued
Item Value: 1,200,000
Item Name: restricted_period
Item Value: 6 months
Item Name: acquisition_completion_date
Item Value: 2025-03-03
Comments
No comments yet. Be the first to comment!